Tower Research Capital LLC (Trc) Nurix Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,849 shares of NRIX stock, worth $64,501. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,849
Previous 6,604
56.86%
Holding current value
$64,501
Previous $137,000
54.01%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$154 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$96.9 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$90.8 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$87.9 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$87.6 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.07B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...